Clinical Trial Update: A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D [Phase 2]

View source ↗

Summary

Phase 2 randomized study evaluating three dosing regimens of Myrcludex B with tenofovir versus tenofovir alone for chronic hepatitis D; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Hepatitis D

Drugs mentioned

• Myrcludex B (bulevirtide)
• Tenofovir (Tenofovir)

Snippet

Sponsor: Hepatera Ltd. | Conditions: Chronic Hepatitis D Infection With Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2019-12-30